AMGN
Amgen

Conference date: February 6, 2024 @ 5:00 AM Pacific Time

Horizon Therapeutics Acquisition a Good Deal for Amgen [December 12, 2022 @ Seeking Alpha]

Amgen Still A Buy After Joining The Dow [September 5, 2020 @ Seeking Alpha]

Amgen A Buy On Otezla Revenue [April 23, 2020 @ Seeking Alpha]

Analyst Conference Summaries and reports available:

2023
Amgen
Q1 2023
Call Notes
Amgen
Q2 2023
Call Notes
Amgen
Q3 2023
Call Notes
Amgen
Q4 2023
Call Notes
April 27, 2022 Aug. 3, 2023 Oct. 31, 2023 Feb. 6, 2024
2022
Amgen
Q1 2022
Call Notes
Amgen
Q2 2022
Call Notes
Amgen
Q3 2022
Call Notes
Amgen
Q4 2022
Call Notes
April 27, 2022 August 4, 2022 Nov. 3, 2022 January 31, 2023
2021
Amgen
Q1 2021
Call Notes
Amgen
Q2 2021
Call Notes
Amgen
Q3 2021
Call Notes
Amgen
Q4 2021
Call Notes
April 27, 2021 Aug. 3, 2021 Nov. 2, 2021 Feb. 8, 2022
2020
Amgen
Q1 2020
Call Notes
Amgen
Q2 2020
Call Notes
Amgen
Q3 2020
Call Notes
Amgen
Q4 2020
Call Notes
April 30, 2020 July 28, 2020 Oct. 28, 2020 Feb. 2, 2021
2019
Amgen
Q1 2019
Call Notes
Amgen
Q2 2019
Call Notes
Amgen
Q3 2019
Call Notes
Amgen
Q4 2019
Call Notes
April 30, 2019 July 30, 2019 Oct. 29, 2019 Jan. 30, 2020
2018
Amgen
Q1 2018
Call Notes
Amgen
Q2 2018
Call Notes
Amgen
Q3 2018
Call Notes
Amgen
Q4 2018
Call Notes
April 24, 2018
July 26, 2018
Oct. 30, 2018
Jan. 29, 2019
2017
Amgen
Q1 2017
Call Notes
Amgen
Q2 2017
Call Notes
Amgen
Q3 2017
Call Notes
Amgen
Q4 2017
Call Notes
April 26, 2017
July 25, 2017
October 25, 2017
February 1, 2018
2016
Amgen
Analyst Call Notes Q1 2016
Amgen
Analyst Call Notes Q2 2016
 Amgen
Analyst Call
Notes Q3 2016
Amgen
Analyst Call
Notes Q4 2016
04/28/2016
07/27/2016
10/27/2016
02/02/2017
2015
Amgen
Analyst Call Notes Q1 2015
Amgen
Analyst Call Notes Q2 2015
Amgen
Analyst Call
Notes Q3 2015

 Amgen
Analyst Notes
Q4 2015
04/21/2015
07/30/2015
 10/28/2015
01/28/2016
2014
Amgen
Analyst Call Notes
Q1 2014
Amgen
Analyst Call Notes
Q2 2014
Amgen
Analyst Call Notes
Q3 2014
Amgen
Analyst Call Notes
Q4 2014
4/22/2014
07/29/2014
10/27/2014
01/27/2015
2013
Not available
Amgen
Analyst Call
Q2 2013
Amgen
Analyst Call
Q3 2013
Amgen
Analyst Call
Q4 2013
 
07/30/2013
10/22/2013
01/28/2014

Amgen's AMG 510 Targeted Cancer Therapy [October 4, 2019 @ Seeking Alpha]

Amgen Evenity Approval Makes It A Hold [April 18, 2019 @ Seeking Alpha]

Amgen Should Rebound [June 20, 2018 @ Seeking Alpha]

BiTE Amgen for Long-term Returns [December 16, 2017 @ Seeking Alpha]

Amgen Valuation Now Excludes Potential Repatha Revenues [February 13, 2016]

FDA Approves Repatha [Amgen press release August 27, 2015]

Amgen 2014 Business Review Notes October 28, 2014
Amgen initial purchase March 24, 2014
Amgen with Onyx Pharmaceuticals: Long Term Analysis September 4, 2013
Amgen Valuation [blog 12/3/2007]

I did not follow Amgen closely between the end of 2008 and mid-2013. I did own Onyx Pharmaceuticals during most of that time.

2008
Amgen analyst conference summary Q3 2008
Amgen analyst conference summary Q2 2008
Amgen Q1 2008 analyst conference summary
Amgen analyst conference summary Q4 2007
Q3 2008
Q2 2008
Q1 2008
Q4 2007
10/22/2008
07/28/2008
04/24/2008
1/24/2008
2007
Amgen Q3 analyst conference summary
amgn Q2 2007
amgen summary
10/24/2007
07/26/2007
4/23/2007

 01/25/2007
Q3 2007
Q2 2007
Q1 2007

 Q4 2006

Amgen is a biotechnology therapeutics company selling a variety of drugs, notably Arenesp, Epogen and Enbrel.

I own Amgen

Amgen Web site:

Amgen home page
investor page

Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but its possible. I am simply sharing my personal notes, not advising anyone about investments.

Copyright 2023 William P. Meyers